Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15825796 | 0.74 | EGFR (1.00) | EGFRPIK3CDPIK3CAFGFR4TDO2 | |
| SCHEMBL15824972 | 0.69 | EGFR (0.71) | EGFRPIK3CDPIK3CAARFGFR4 | |
| SCHEMBL3126931 | 0.68 | AR (0.55) | EGFRAR | |
| Hydrochloric Acid SCHEMBL28690143 | 0.67 | EGFR (0.54) | EGFRPIK3CDPIK3CAARNAMPT | |
| SCHEMBL4312105 | 0.65 | TSPO (0.51) | EGFRPIK3CDPIK3CAARNAMPT | |
| SCHEMBL13480994 | 0.65 | EGFR (0.59) | EGFRAR | |
| SCHEMBL4156184 | 0.65 | EGFR (0.55) | EGFRPIK3CDPIK3CAARFGFR4 | |
| Acetic Acid SCHEMBL3176517 | 0.64 | EGFR (0.50) | EGFRPIK3CDPIK3CAARFGFR4 | |
| SCHEMBL3098888 | 0.64 | EGFR (0.47) | EGFRPIK3CDPIK3CAARFGFR4 | |
| SCHEMBL29906862 | 0.64 | EGFR (0.53) | EGFRPIK3CDPIK3CAARNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786131-B2 | Anticancer agents; restenosis; atherosclerosis; skin disorders | WARNER-LAMBERT COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885PIK3CD 684/4885PIK3CA 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.